<DOC>
	<DOCNO>NCT01518309</DOCNO>
	<brief_summary>This open-label extension study ass long-term safety tolerability pimavanserin ( ACP-103 ) subject Parkinson 's Disease Psychosis ( PDP ) .</brief_summary>
	<brief_title>An Open-label Safety Study Pimavanserin Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>Inclusion Criteria Patients age , male female clinical diagnosis idiopathic Parkinson 's disease , participate previous ( Phase II ) clinical trial evaluate pimavanserin Patients may , opinion treat physician , benefit continued therapy pimavanserin Patient willing able provide consent Exclusion Criteria Female patient childbearing potential Patient clinically significant concurrent medical illness Patient judge treat physician inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>